Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Nonclinical Factors and Patient Conversations that Shape Treatment Success

July 16th 2025

Panelists discuss how nonclinical factors including drug costs, insurance coverage, work situations, patient intelligence for complex dosing schedules, and comprehensive pretreatment education about toxicities like hyperglycemia, rash, and diarrhea are crucial for successful implementation of the triplet regimen.

Beyond PIK3CA Status: A Case-Based Approach to Multifactor Inavolisib Selection

July 16th 2025

Panelists discuss how to identify ideal candidates for triplet therapy using a case example, emphasizing the importance of endocrine resistance, disease burden, performance status, and careful management of hyperglycemia risk through baseline hemoglobin A1C (HbA1C) assessment and proactive glucose monitoring strategies.

Dr Jones on the Implications of Data from ASCENT-04 for First-Line PD-L1+ TNBC Management

July 15th 2025

Jade E. Jones, MD, discusses the importance of identifying the most effective first-line treatment regimen for PD-L1–positive TNBC.

Adjuvant Dalpiciclib Plus Endocrine Therapy Improves iDFS in HR+/HER2– Early Breast Cancer

July 14th 2025

Adjuvant dalpiciclib plus endocrine therapy met the iDFS primary end point in the DAWNA-A trial in HR-positive, HER2-negative early breast cancer.

Dr Tan on the Clinical Relevance of T-DXd in HER2-Low/Ultralow Metastatic Breast Cancer

July 11th 2025

Antoinette Tan, MD, MHS, discusses the implications of the DESTINY-Breast06 trial of T-DXd vs chemotherapy in HER2-low or -ultralow breast cancer.

Dr McArthur on the Efficacy of Pembrolizumab Plus Neoadjuvant Chemo in TNBC

July 11th 2025

Heather McArthur, MD, MPH, FASCO, discusses the efficacy of pembrolizumab/chemo and sequencing the regimen in early triple-negative breast cancer.

Patritumab Deruxtecan Shows CNS Efficacy in Metastatic Breast Cancer With Brain Metastases

July 10th 2025

Treatment with HER3-DXd led to intracranial responses with a tolerable safety profile in patients with metastatic breast cancer and brain metastases.

Real-World ctDNA Positivity Predicts Poorer Outcomes in Early Breast Cancer

July 9th 2025

Real-world analysis showed ctDNA positivity was associated with higher recurrence risk and reduced overall survival in early breast cancer.

Precision Medicine: Navigating PI3K Inhibitor Choices in Clinical Practice

July 9th 2025

Panelists discuss how to contextualize inavolisib within the broader landscape of PIK3CA inhibitors, noting its improved tolerability compared with alpelisib while emphasizing the need for individualized treatment selection based on disease burden and the emerging challenge of managing comutations like ESR1.

Time to Chemotherapy Delayed by 2 Years: How Inavolisib Combination Data Might Inform Treatment Sequencing

July 9th 2025

Panelists discuss how the INAVO120 trial’s secondary end point showing delayed time to chemotherapy from 12 to 36 months with the triplet combination provides compelling quality-of-life benefits for patients while acknowledging the challenges of determining optimal treatment sequencing after progression on this regimen.

Bria-IMT Plus Checkpoint Inhibition Leads to 52% 1-Year OS Rate in Heavily Pretreated Metastatic Breast Cancer

July 8th 2025

Bria-IMT plus checkpoint inhibition displayed a potential overall survival benefit in heavily pretreated, hormone receptor–positive breast cancer.

Five Under 5: Top Oncology Videos for the Week of 6/29

July 6th 2025

The top 5 OncLive videos of the week cover insights in myelofibrosis, AL amyloidosis, pancreatic cancer, and PIK3CA-mutated breast cancer.

Dr Cardoso on the Effect of Elinzanetant on Vasomotor Symptoms in HR+ Breast Cancer

July 3rd 2025

Fatima Cardoso, MD, MSc, FESMO, discusses the use of elinzanetant for vasomotor symptoms in women receiving endocrine therapy for HR+ breast cancer.

Dr Ansley on Inavolisib Plus Palbociclib/Fulvestrant in PIK3CA-Mutated HR+/HER2– Breast Cancer

June 30th 2025

Katherine C. Ansley, MD, discusses the importance of the phase 3 INAVO120 trial in PIK3CA-mutated, hormone receptor–positive, HER2-negative breast cancer.

INAVO120 Final Analysis: Translating Overall Survival Data into Clinical Practice

June 30th 2025

Panelists discuss how the INAVO120 trial's final overall survival analysis showing a 7-month median survival benefit (34 vs 27 months) with inavolisib plus palbociclib plus fulvestrant in PIK3CA-mutated endocrine resistant breast cancer represents promising but complex data, given the low crossover rates and potential need for first-line PIK3CA inhibitor use before patients progress to chemotherapy.

2025 Giants of Cancer Care: OncLive® Honors 13 Cancer Care Pioneers

June 30th 2025

OncLive® showcases 13 cancer care pioneers, who have won the 2025 Giants of Cancer Care award.

Five Under 5: Top Oncology Videos for the Week of 6/22

June 29th 2025

The top 5 OncLive videos of the week cover insights in myelofibrosis, lung cancer, ovarian cancer, breast cancer, and melanoma.

Dr El-Saghir on the Implications of the RIGHT Choice Trial of Ribociclib Plus ET in HR+, HER2– Advanced Breast Cancer

June 27th 2025

Nagi S. El-Saghir, MD, FACP, FASCO, discusses the clinical implications of the phase 2 RIGHT Choice trial.

Dr McCann on the Importance of Reaching Consensus on the Role of Vepdegestrant in ER+ Breast Cancer

June 25th 2025

Kelly McCann, MD, PhD, discusses the need to reach consensus on the potential role of vepdegestrant for ER-positive, HER2-negative advanced breast cancer.

Skipping Surgery in Early HER2+ Breast Cancer or TNBC? Phase 2 Trial Data Highlight Feasibility of Selective Omission

June 24th 2025

Henry Kuerer, MD, PhD, discusses considerations for the selective omission of surgery in HER2-positive breast cancer or triple-negative breast cancer.